FDA Inspection 1219319 — Teva Pharmaceuticals USA, Inc

Teva Pharmaceuticals USA, Inc — FEI 3003092769

The FDA completed an inspection of Teva Pharmaceuticals USA, Inc on Sep 29, 2023 in Parsippany, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Sep 29, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Parsippany, NJ (United States)

Additional Details

Risk Evaluation and Mitigation Strategies (REMS)

Citations

IDCFRDescription
21360FDCA 505-1(f)(4)Failure to comply with REMS Implementation System

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.